This direct path to a registrational trial without a required Phase 2 is highly unusual and de-risks development. Traders should monitor trial initiation and patient enrollment trends; success could position Ryoncil® as a first-in-class anti-inflammatory therapy for DMD, significantly expanding its market potential beyond SR-aGvHD.
MESO drugs
MESO drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $14.70entry
- T+1 · 7mo ago −0.61%α −1.82% · $14.61
- T+5 · 7mo ago +12.99%α +9.70% · $16.61
- T+20 · 6mo ago −1.29%α −9.02% · $14.51
- T+60 · 4mo ago +0.68%α −8.24% · $14.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mesoblast received FDA clearance to proceed directly into a registrational trial for Ryoncil® (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), a rare and fatal muscle-wasting disease affecting ~15,000 children in the U.S. The Phase 3 trial will enroll 76 patients aged 5–9, with primary endpoint of time-to-stand at nine months.
Key Facts
- FDA granted IND clearance for a registrational trial of Ryoncil® in Duchenne muscular dystrophy (DMD).
- Trial will enroll 76 pediatric patients (ages 5–9), randomized to Ryoncil® or placebo, with time-to-stand at 9 months as the primary endpoint.
- Ryoncil® is already FDA-approved for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children, supporting its safety profile.
- Mesoblast is partnering with Parent Project Muscular Dystrophy (PPMD) and the Duchenne Registry for patient identification and trial awareness.
Financial Impact
Potential blockbuster expansion into a new pediatric indication with no approved disease-modifying therapies targeting inflammation in DMD.
Risk Factors
- Clinical failure in the registrational trial despite strong preclinical data.
- Limited sample size (76 patients) may raise concerns about statistical power.
- Competition from gene therapies and exon-skipping drugs targeting dystrophin restoration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272039 |
Track record
25 reports on MESO
7 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
- Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
- Oct 29, 202618d ago 6-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
- Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
- Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
- Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers